Antibe Therapeutics Inc(Pre-Merger) ATBPF

Not much to say ...

[MrMugsy]

Not much to say until we hear back.

In Phase 2 those on 200 mg dose consumed 2800 mg in total (over 14 days).
Now, at 100 mg dose, they consumed 2800 mg over a 28 day period.
Something doesn't make sense - what's at play ?

Waiting for some understanding.

[Doccole]

Keep your head up and I will follow. hopefully this shakes out better.  Retail is emotional and we are owned big time by retail investors.  No point in being sad, keep the thick skin and hope for the best. big cash position keeps us in business for a while, even if we have to pivot.  No ideal, not the end of the world!

[sidtheritz]

Agree. Also note the following for phase 2:  During the treatment period, only 1 out of 318 patients administered otenaproxesul had clinically significant, temporary liver enzyme elevations (“LTEs”) — this is a known “class effect” of NSAIDs At the post-treatment assessment, patients in the 250 mg, 200 mg and 150 mg treatment arms had LTE incidences of 12.9%, 7.2% and 9.8

[woundedknee]

Yes, that is a head shaker. Only thing it could be is a 200mg dose every second day and a 100 mg dose once daily.

[TriumphSpitSix]

Barring external factors (which I still think are the real cause) the below would point to some characteristic of 346 that is not dose dependent but that takes 3+ weeks to manifest elevated LTEs regardless of dose size. Seems counter-intuitive and unlikely but, sigh, not out of the realm of possibility until they finalize the investigation.